Mirum Pharmaceuticals (FRA:08D) FCF Margin % : -6.86% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mirum Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2024 was €-5.6 Mil. Mirum Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was €81.4 Mil. Therefore, Mirum Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2024 was -6.86%.

As of today, Mirum Pharmaceuticals's current FCF Yield % is -1.33%.

The historical rank and industry rank for Mirum Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:08D' s FCF Margin % Range Over the Past 10 Years
Min: -793.09 Med: -156.26 Max: -8.88
Current: -8.88

During the past 6 years, the highest FCF Margin % of Mirum Pharmaceuticals was -8.88%. The lowest was -793.09%. And the median was -156.26%.

FRA:08D's FCF Margin % is ranked better than
72.15% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs FRA:08D: -8.88

Mirum Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Mirum Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals FCF Margin % Chart

Mirum Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-793.10

-156.25

-48.86

Mirum Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-38.18	-31.08	21.96	-18.73	-6.86

Competitive Comparison of Mirum Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Mirum Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirum Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's FCF Margin % falls into.

Mirum Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mirum Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-83.496	/	170.905
	=	-48.86 %

Mirum Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-5.583	/	81.43
	=	-6.86 %

Mirum Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MIRM:USA MIRM:Mexico 08D:Germany

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals Headlines

No Headlines